Funding for this research was provided by:
National Institutes of Health (R01-HL126990)
Received: 5 May 2018
Accepted: 24 September 2018
First Online: 3 October 2018
Ethics approval and consent to participate
: The ILD registry at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease and the Lung Cancer registry at the Hillman Cancer Center were approved by the Institutional Review Board (# 0307127, modified 0307127–12) at the University of Pittsburgh.
: Both registries’ data were collected with consent from individual patient at the time of enrollment throughout data collection period.
: JHY, MN, XC, JC, KV, KL, DOW and SY have nothing to disclose.JS reports grants from Boehringer, grants and personal fees from Roche, personal fees from Rovi, outside the submitted work. TB reports personal fees from AbbVIE and Regeneron, outside the submitted work. NK reports grant and personal fees from Biogen Idec, personal fees from MMI, non-financial support from Actelion, non-financial support from Miragen, non-financial support from Astra Zeneca, non-financial support from GSK, personal fees from Pilant, and is a consultant to Samumed, Numedii, which are outside the submitted work. NK is also a member of the Scientific Advisory Committee, the Research Advisory Forum, and the Board of the Pulmonary Fibrosis Foundation, as well as serving as Deputy Editor of Thorax and BMJ. KG reports personal fees from Bayer, outside the submitted work. DJK reports research grant funding from Regeneron, outside the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.